SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lamers, K J.
Right arrow Articles by Jongen, P J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamers, K J.
Right arrow Articles by Jongen, P J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis

K JB Lamers

University Hospital Nijmegen, Institute of Neurology, Laboratory of Neurology, PO Box 9101, 6500 HB Nijmegen

H PM de Reus

University Hospital Nijmegen, Institute of Neurology, Laboratory of Neurology, PO Box 9101, 6500 HB Nijmegen

P JH Jongen

MS Center, Nijmegen, The Netherlands

There is an evident need for a quantitative laboratory marker for ascertaining disease activity and treatment effects in multiple sclerosis (MS) patients. Activity of the disease process in MS is accompanied by myelin breakdown and appearance of myelin basic protein (MBP) in cerebrospinal fluid (CSF). In this paper MBP in CSF of relapsing-remitting (RR) MS patients is reviewed. MBP in CSF is a fragment containing an epitope corresponding to aminoacid residues 45-89 of the native molecule. From several relevant studies about CSF MBP in RR MS the following relations can be concluded: CSF MBP levels in active MS patients are frequently increased (45-100%), remain increased until 5 to 6 weeks after onset symptoms and are higher in polysymptomatic exacerbations and correlate with number of gadolinium-enhanced (Gd) lesions on MRI, severity of relapses, EDSS score and CSF intrathecal IgM synthesis. After an intravenous methylprednisolone treatment the increased CSF MBP levels return to normal values and reduction in CSF MBP is related to reduction in EDSS score, number of Gd lesions and CSF intrathecal IgM synthesis.

Key Words: multiple sclerosis • cerebrospinal fluid • MBP • methylprednisolone

Multiple Sclerosis, Vol. 4, No. 3, 124-126 (1998)
DOI: 10.1177/135245859800400306


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
A. F. de Vos, M. van Meurs, H. P. Brok, L. A. Boven, R. Q. Hintzen, P. van der Valk, R. Ravid, S. Rensing, L. Boon, B. A. 't Hart, et al.
Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs
J. Immunol., November 15, 2002; 169(10): 5415 - 5423.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
K G Warren and I. Catz
Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients
Multiple Sclerosis, October 1, 2000; 6(5): 300 - 311.
[Abstract] [PDF]



Advertisement